Mark Breidenbach
Stock Analyst at Oppenheimer
(1.68)
# 3,365
Out of 5,012 analysts
57
Total ratings
33.33%
Success rate
0.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $9 → $7 | $1.47 | +376.19% | 6 | Aug 1, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $9.98 | +200.60% | 4 | Sep 4, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $0.20 | +8,349.30% | 5 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $9.75 | +874.36% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $6.50 | +284.62% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.86 | +1,065.50% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $19.64 | +1,122.00% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $4.40 | +3,536.36% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.81 | +286.74% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $2.68 | +1,094.03% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $15 | $2.27 | +560.79% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.74 | +6,816.43% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $1.74 | +560,244.83% | 2 | May 12, 2020 |
Allogene Therapeutics
Aug 1, 2025
Maintains: Outperform
Price Target: $9 → $7
Current: $1.47
Upside: +376.19%
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $9.98
Upside: +200.60%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $0.20
Upside: +8,349.30%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $9.75
Upside: +874.36%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $6.50
Upside: +284.62%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.86
Upside: +1,065.50%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $19.64
Upside: +1,122.00%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $4.40
Upside: +3,536.36%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.81
Upside: +286.74%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $2.68
Upside: +1,094.03%
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $2.27
Upside: +560.79%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.74
Upside: +6,816.43%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $1.74
Upside: +560,244.83%